CN114469938A - 化合物bix02189在制备抗流感病毒药物中的应用 - Google Patents
化合物bix02189在制备抗流感病毒药物中的应用 Download PDFInfo
- Publication number
- CN114469938A CN114469938A CN202011161113.1A CN202011161113A CN114469938A CN 114469938 A CN114469938 A CN 114469938A CN 202011161113 A CN202011161113 A CN 202011161113A CN 114469938 A CN114469938 A CN 114469938A
- Authority
- CN
- China
- Prior art keywords
- influenza
- compound
- bix02189
- subtype
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 76
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 206010022000 influenza Diseases 0.000 title abstract description 36
- 241000700605 Viruses Species 0.000 title abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 230000009385 viral infection Effects 0.000 claims abstract description 12
- 239000003443 antiviral agent Substances 0.000 claims abstract description 9
- -1 amino acid salt Chemical class 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 150000007942 carboxylates Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 3
- 208000037797 influenza A Diseases 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical class CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 229940050390 benzoate Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 claims description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims description 2
- 229940114081 cinnamate Drugs 0.000 claims description 2
- 229940001468 citrate Drugs 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940050411 fumarate Drugs 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical class CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 claims 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 208000037798 influenza B Diseases 0.000 claims 1
- 208000037799 influenza C Diseases 0.000 claims 1
- 208000037800 influenza D Diseases 0.000 claims 1
- 150000003871 sulfonates Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 59
- 230000000694 effects Effects 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 22
- 241000712431 Influenza A virus Species 0.000 description 13
- 241000197306 H1N1 subtype Species 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 241000252870 H3N2 subtype Species 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 229960000329 ribavirin Drugs 0.000 description 7
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 7
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101001115390 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 5 Proteins 0.000 description 6
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 6
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000713196 Influenza B virus Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 229960003805 amantadine Drugs 0.000 description 3
- 229940124393 anti-influenza virus drug Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000012200 cell viability kit Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960000888 rimantadine Drugs 0.000 description 3
- 230000001932 seasonal effect Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241001473004 H10N7 subtype Species 0.000 description 2
- 241000827370 H10N8 subtype Species 0.000 description 2
- 241000827380 H11N2 subtype Species 0.000 description 2
- 241000620997 H11N9 subtype Species 0.000 description 2
- 241000397491 H17N10 subtype Species 0.000 description 2
- 241000827773 H18N11 subtype Species 0.000 description 2
- 241000197305 H1N2 subtype Species 0.000 description 2
- 241000197304 H2N2 subtype Species 0.000 description 2
- 241000197183 H2N3 subtype Species 0.000 description 2
- 241000040247 H3N1 subtype Species 0.000 description 2
- 241000252869 H3N8 subtype Species 0.000 description 2
- 241001473385 H5N1 subtype Species 0.000 description 2
- 241000252843 H5N2 subtype Species 0.000 description 2
- 241000252845 H5N3 subtype Species 0.000 description 2
- 241000048433 H5N6 subtype Species 0.000 description 2
- 241000617520 H5N8 subtype Species 0.000 description 2
- 241001231806 H5N9 subtype Species 0.000 description 2
- 241000252872 H6N1 subtype Species 0.000 description 2
- 241000252871 H6N2 subtype Species 0.000 description 2
- 241000252866 H7N1 subtype Species 0.000 description 2
- 241000252864 H7N2 subtype Species 0.000 description 2
- 241000252863 H7N3 subtype Species 0.000 description 2
- 241001676764 H7N4 subtype Species 0.000 description 2
- 241000252868 H7N7 subtype Species 0.000 description 2
- 241000342557 H7N9 subtype Species 0.000 description 2
- 241001473386 H9N2 subtype Species 0.000 description 2
- 241000134304 Influenza A virus H3N2 Species 0.000 description 2
- 241000713297 Influenza C virus Species 0.000 description 2
- 241000401051 Influenza D virus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940126181 ion channel inhibitor Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012660 pharmacological inhibitor Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FIDLLEYNNRGVFR-CTNGQTDRSA-N (3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione Chemical compound OC1=C2N(C=CC1=O)N([C@@H]1COCCN1C2=O)[C@@H]1C2=C(SCC3=C1C=CC(F)=C3F)C=CC=C2 FIDLLEYNNRGVFR-CTNGQTDRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JDQDSEVNMTYMOC-UHFFFAOYSA-M 3-methylbenzenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-M 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101710084687 Cyclin-dependent kinase 2 homolog Proteins 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 229940123734 Endonuclease inhibitor Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 101150043871 MAPK7 gene Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700027650 Mitogen-Activated Protein Kinase 7 Proteins 0.000 description 1
- 102000046796 Mitogen-Activated Protein Kinase 7 Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 1
- 229940008411 baloxavir marboxil Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药技术领域,公开了化合物BIX02189在制备抗流感病毒药物中的应用,具体公开了如结构式(I)所示的化合物BIX02189或其药学上可接受的盐在制备预防或治疗流感病毒感染的药物中的应用。以及包括化合物BIX02189与其他抗病毒药物的联合应用。
Description
技术领域
本发明属于医药技术领域,具体涉及化合物BIX02189(CAS:1094614-85-3)制备预防或治疗流感病毒感染的药物中的应用。本发明包含化合物BIX02189在流感病毒感染预防或治疗中的单独或联合应用。
背景技术
流感病毒(Influenza virus)是对全球公共卫生安全的重要威胁,据世界卫生组织(WHO)统计,每年约有5-10%成人和20-30%的儿童感染流感病毒,其中300-500万为重症患者,死亡人数约25-50万人[Ziegler T,Mamahit A,Cox NJ:65years of influenzasurveillance by a world health organization-coordinated globalnetwork.Influenza and other respiratory viruses(2018)12(5):558-565.]。流感病毒属于正粘病毒科(Orthomyxoviridae),分甲、乙、丙和丁共四型,其中甲、乙和丙型流感病毒可感染人并引起呼吸道疾病。甲型流感病毒流行范围最广,危害最大。其中1918年西班牙流感疫情致5000万人死亡;而2009年猪流感病毒疫情,也造成全球约57万人死亡[Firstglobal estimates of 2009h1n1pandemic mortality released by cdc-ledcollaboration:(2012).https://www.cdc.gov/flu/spotlights/pandemic-global-estimates.htm]。
流感病毒呈球形,直径约80-120nm,是包膜病毒,其基因组是单链分节段RNA。甲型流感病毒共有8条RNA,编码至少10种病毒蛋白[David M Knipe P,Peter M Howley,MD:Fields virology,6th edition.2.Lippincott Williams&Wilkins(LWW),(2013)]。流感病毒包膜来自宿主细胞膜,上面嵌有三种病毒蛋白:血凝素蛋白(Hemagglutinin,HA)、神经氨酸酶(Neuraminidase,NA)和M2离子通道。甲型流感病毒根据HA和NA血清学分类,已知有18种HA和10种NA,故理论上共有180种亚型。流行病学数据显示,曾引起大规模致死性流感疫情的有H1N1亚型(1918年西班牙流感和2009年猪流感)、H2N2亚型(1950年亚洲流感)、H3N2亚型(1960年香港流感)。
除流感大流行外,季节性流感每年都会出现,主要发生在冬季,最常由甲型或乙型流感病毒引起,其中以H1N1和H3N2较为常见。患季节性流感后的症状包括突然发热、咳嗽(通常是干咳)、头痛、肌肉和关节疼痛、喉咙痛和流鼻涕。咳嗽可能很严重,可持续2周或更长时间。大多数人在一周内从发烧和其它症状中恢复,不需要进行医疗。然而,流感可导致高危群体的严重疾病或死亡。[How can I avoid getting the flu?World HealthOrganization website:https://www.who.int/news-room/q-a-detail/how-can-i-avoid-getting-the-flu]
现有抗流感病毒药物包括三类共7个[Amarelle L,Lecuona E,Sznajder JI:Anti-influenza treatment:Drugs currently used and under development.Archivosde bronconeumologia(2017)53(1):19-26.]:M2离子通道抑制剂金刚烷胺和金刚乙胺;神经氨酸酶抑制剂奥司他韦、扎那米韦、帕拉米韦和拉尼米韦;CAP依赖核酸内切酶抑制剂巴洛沙韦玛波西酯(baloxavir marboxil)。这7个抗流感病毒药物有一个共性:它们都是以流感病毒蛋白为靶点的药物,所以,当靶点变异时,药物亲和力下降,流感病毒逃逸,成为耐药病毒。例如流感病毒M2离子通道抑制剂金刚烷胺和金刚乙胺经过长期使用,病毒已产生稳定耐药突变,WHO已不推荐金刚烷胺和金刚乙胺用于甲型流感病毒的治疗[Summary ofinfluenza antiviral susceptibility surveillance findings,September 2010-march2011:(2011).https://www.who.int/influenza/gisrs_laboratory/updates/antiviral_susceptibility/en/]。
虽然有7个曾经或正在使用的抗流感病毒药物,但全球每年仍有5-15亿人次流感病毒感染并患病。美国疾控中心统计,2010-2018年,全美每年感染甲型流感病毒患者人数930-4900万,死亡1.2-7.9万[Influenza(flu):(2020).https://www.cdc.gov/flu/about/burden/index.html];也就是,在有抗流感病毒药物供应及注射流感病毒疫苗后,全部人口中仍有5%-20%感染患病,究其原因,主要由于流感病毒本身性质和变异和其RNA基因组的重组(Reassortment)引起的。例如,神经氨酸酶抑制剂是临床最常用的抗甲型流感病毒药物,其中以奥司他韦(达菲)应用最广,临床数据显示,患者只有在感染病毒48小时内服药才可获得较好疗效[Summary of influenza antiviral susceptibility surveillancefindings,September 2010-March 2011:(2011).https://www.who.int/influenza/gisrs_laboratory/updates/antiviral_susceptibility/en/]。
化合物BIX02189是由美国勃林格殷格翰制药公司(Boehringer IngelheimPharmaceuticals)研发的丝裂原活化细胞外信号调节激酶5(MEK5)抑制剂,对MEK5的半数抑制浓度(IC50)为1.5nM[Tatake RT,et al.Identification of pharmacologicalinhibitors of the MEK5/ERK5 pathway.Biochem Biophys Res Commun,2008,377(1):120-125]。MEK5/ERK5在MAPKK信号通路起重要作用,与肿瘤[Hayashi M,et al.Bigmitogen-activated protein kinase 1/extracellular signal-regulated kinase5signaling pathway is essential for tumor-associated angiogenesis,CancerRes.2005,65(17):7699-7706]、神经[Watson FL,Neurotrophinsuse the Erk5 pathwayto mediate a retrograde survival response.Nat.Neurosci.2001,4(10):81-88.]和心血管系统功能和病变密切相关[Wang X,et al.Targeted deletion of mek5 causesearly embryonic death and defects in the extracellular signal-regulatedkinase 5/myocyte enhancer factor 2cell survival pathway.Mol.Cell.Biol.2005,25(1):336–345.]。
研究显示,除MEK5外,化合物BIX02189还可抑制ERK5激酶活性,IC50为59nM,但对MEK1、MEK2和JNK2等激酶活性无显著影响[Tatake RT,et al.Identification ofpharmacological inhibitors of the MEK5/ERK5 pathway.Biochem Biophys ResCommun,2008,377(1):120-125]。有研究显示,化合物BIX02189可靶向TGF-βI型受体,抑制肺癌细胞的转移[Park SJ,et al.BIX02189 inhibits TGF-β1-induced lung cancercell metastasis by directly targeting TGF-βtype I receptor.Cancer Lett.2016,381(2):314-322]。化合物BIX02189还可抑制ERK2激酶活性,下调TGF-β1-Smad信号通路,降低博来霉素诱导的肺部纤维化小鼠的死亡率[Kim S,et al.Inhibition of ERK5protects pulmonary fibrosis via downregulation of TGF-b1-Smad signaling.FASEBJournal,2013,27:1031-1035]。此外,化合物BIX02189通过抑制新生大鼠心肌细胞(NRCMs)中ERK5的磷酸化过程,降低心肌细胞增强因子2(MEF2)转录活性,上调山梨醇诱导的心肌细胞凋亡[Kimura TE,et al.Targeted deletion of the extracellular signal-regulated protein kinase 5attenuates hypertrophic response and promotespressure overload-induced apoptosis in the heart.Circ Res,2010,106(5):961-970.]。经文献检索,未见关于化合物BIX02189抗流感病毒活性的报道。
本发明应用流感病毒感染模型,对已知化合物/上市药物进行抗病毒活性评价,发现化合物BIX02189具有广谱抗流感病毒活性,对甲型和乙型流感病毒感染有较强抑制活性。数据显示化合物BIX02189抗流感病毒活性与一线抗病毒药物利巴韦林相当,其中抗甲型流感病毒活性强于利巴韦林,且化合物BIX02189安全性良好。我们认为化合物BIX02189抗流感病毒新用途价值较高,具有应用前景。本发明是关于已知化合物新用途的发明专利。
发明内容
本发明解决的技术问题是,提供化合物BIX02189及其药学上可接受的盐在制备预防或治疗流感病毒感染的药物中的应用。
具体而言,为解决本发明的技术问题,采用如下技术方案:
本发明技术方案的第一方面是提供了如结构式(I)所示的化合物BIX02189及其药学上可接受的盐在制备预防或治疗流感病毒药物中的应用,
所述的化合物BIX02189的药学上可接受的盐,包括药学上可接受的有机盐或无机盐,其中,所述的有机盐包括磺酸盐、羧酸盐、氨基酸盐以及脂肪酸盐,无机盐包括盐酸盐、溴酸盐、碘酸盐、硫酸盐、硫酸氢盐、磷酸盐、磷酸氢盐、磷酸二氢盐和硝酸盐。优选为硫酸氢盐,硫酸盐,盐酸盐和碘酸盐。
所述的磺酸盐包括含1-15个碳原子的烷基磺酸盐及苯磺酸盐、对甲苯磺酸盐、邻甲苯磺酸盐、间甲苯磺酸盐;羧酸盐包括酒石酸盐、马来酸盐、富马酸盐、枸橼酸盐、苹果酸盐、肉桂酸盐、苯甲酸盐、丙二酸盐、丁二酸盐、戊二酸盐、己二酸盐、双羟萘酸盐及乳酸盐;氨基酸盐包括谷氨酸盐、天冬氨酸盐;脂肪酸盐包括含2-18个碳原子的长链脂肪酸盐。
其中,所述的流感病毒包括甲型流感病毒、乙型流感病毒、丙型流感病毒和丁型流感病毒。
所述的甲型流感病毒包括H1N1亚型、H1N2亚型、H2N2亚型、H2N3亚型、H3N1亚型、H3N2亚型、H3N8亚型、H5N1亚型、H5N2亚型、H5N3亚型、H5N6亚型、H5N8亚型、H5N9亚型、H6N1亚型、H6N2亚型、H7N1亚型、H7N2亚型、H7N3亚型、H7N4亚型、H7N7亚型、H7N9亚型、H9N2亚型、H10N7亚型、H10N8亚型、H11N2亚型、H11N9亚型、H17N10亚型、H18N11亚型。其中甲型H1N1流感病毒包括A/PurtoRico/8/1934、A/WSN/33、A/湖北洪山/52/2005、A/京防/262/1995、A/广东罗湖/219/2006和A/FM/1/47株;甲型H3N2流感病毒包括A/江西东湖/312/2006、A/济防/15/90、A/粤防/243/1972、A/汉防/359/1995、A/New York/238/2015、A/Brisbane/10/07、A/Perth/16/09和A/Udorn/307/72株。乙型流感病毒包括B/江西新建/BV/39/2008、B/济防/13/1997、B/深圳/155/2005、B/四川/63/2001、B/浙江/2/2001、B/山东/7/97、B/Durban/39/98、B/Shandong Taian Taishan/1219/2009、B/Sichuan/34/2001B/Yamagata/16/88、B/Victoria/2/87、B/Johannesburg/1/99和B/Maputo/1/99株。
本发明技术方案的第二方面提供了一种药物组合物在制备抗流感病毒药物中的应用,其特征在于,所述的药物组合物包含结构式(I)所示的化合物BIX02189及其药学上可接受的盐以及药学上可接受的载体或赋形剂;所述的药物组合物还可以含有其它的抗病毒药
其中,所述的流感病毒包括甲型流感病毒、乙型流感病毒、丙型流感病毒和丁型流感病毒。
所述的甲型流感病毒包括H1N1亚型、H1N2亚型、H2N2亚型、H2N3亚型、H3N1亚型、H3N2亚型、H3N8亚型、H5N1亚型、H5N2亚型、H5N3亚型、H5N6亚型、H5N8亚型、H5N9亚型、H6N1亚型、H6N2亚型、H7N1亚型、H7N2亚型、H7N3亚型、H7N4亚型、H7N7亚型、H7N9亚型、H9N2亚型、H10N7亚型、H10N8亚型、H11N2亚型、H11N9亚型、H17N10亚型、H18N11亚型。其中甲型H1N1流感病毒包括A/PurtoRico/8/1934、A/WSN/33、A/湖北洪山/52/2005、A/京防/262/1995、A/广东罗湖/219/2006和A/FM/1/47株;甲型H3N2流感病毒包括A/江西东湖/312/2006、A/济防/15/90、A/粤防/243/1972、A/汉防/359/1995、A/New York/238/2015、A/Brisbane/10/07、A/Perth/16/09和A/Udorn/307/72株。乙型流感病毒包括B/江西新建/BV/39/2008、B/济防/13/1997、B/深圳/155/2005、B/四川/63/2001、B/浙江/2/2001、B/山东/7/97、B/Durban/39/98、B/Shandong Taian Taishan/1219/2009、B/Sichuan/34/2001B/Yamagata/16/88、B/Victoria/2/87、B/Johannesburg/1/99和B/Maputo/1/99株。
该药物组合物可根据本领域公知的方法制备。可通过将本发明化合物与一种或多种药学上可接受的固体或液体赋形剂和/或辅剂结合,制成适于人或动物使用的任何剂型。
本发明化合物或含有它的药物组合物可以单位剂量形式给药,给药途径可为肠道或非肠道,如口服、静脉注射、肌肉注射、皮下注射、鼻腔、口腔粘膜、眼、肺和呼吸道、皮肤、阴道、直肠等。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂(包括o/w型、w/o型和复乳)、混悬剂、注射剂(包括水针剂、粉针剂和输液)、滴眼剂、滴鼻剂、洗剂和搽剂等;固体剂型可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片)、胶囊剂(包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气(粉)雾剂、喷雾剂等;半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明化合物可以制成普通制剂、也制成是缓释制剂、控释制剂、靶向制剂及各种微粒给药系统。
为了将本发明化合物制成片剂,可以广泛使用本领域公知的各种赋形剂,包括稀释剂、黏合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂可以是淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、硫酸钙、磷酸氢钙、碳酸钙等;湿润剂可以是水、乙醇、异丙醇等;粘合剂可以是淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等;崩解剂可以是干淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、碳酸氢钠与枸橼酸、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠等;润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、酒石酸、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片,例如糖包衣片、薄膜包衣片、肠溶包衣片,或双层片和多层片。
为了将给药单元制成胶囊剂,可以将有效成分本发明化合物与稀释剂、助流剂混合,将混合物直接置于硬胶囊或软胶囊中。也可将有效成分本发明化合物先与稀释剂、黏合剂、崩解剂制成颗粒或微丸,再置于硬胶囊或软胶囊中。用于制备本发明化合物片剂的各稀释剂、黏合剂、润湿剂、崩解剂、助流剂品种也可用于制备本发明化合物的胶囊剂。
为将本发明化合物制成注射剂,可以用水、乙醇、异丙醇、丙二醇或它们的混合物作溶剂并加入适量本领域常用的增溶剂、助溶剂、pH调剂剂、渗透压调节剂。增溶剂或助溶剂可以是泊洛沙姆、卵磷脂、羟丙基-β-环糊精等;pH调剂剂可以是磷酸盐、醋酸盐、盐酸、氢氧化钠等;渗透压调节剂可以是氯化钠、甘露醇、葡萄糖、磷酸盐、醋酸盐等。如制备冻干粉针剂,还可加入甘露醇、葡萄糖等作为支撑剂。
此外,如需要,也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂或其它添加剂。
本发明的发明人发现化合物BIX02189可阻断流感病毒感染宿主细胞。还可以和其他的抗病毒药物进行联合用药。
为达到用药目的,增强治疗效果,本发明的药物或药物组合物可用任何公知的给药方法给药。
本发明化合物药物组合物的给药剂量依照所要预防或治疗疾病的性质和严重程度,患者或动物的个体情况,给药途径和剂型等可以有大范围的变化。
本发明的化合物或组合物可单独服用,或与其他治疗药物或对症药物合并使用。当本发明的化合物与其它治疗药物存在协同作用时,应根据实际情况调整它的剂量。
有益技术效果
本发明的发明人通过对300余个已知化合物进行抗流感病毒感染活性评价,发现MEK5抑制剂化合物BIX02189对甲型和乙型流感病毒感染有较强抑制活性,数据显示化合物BIX02189抗流感病毒活性与一线抗病毒药物利巴韦林相当,其中抗甲型流感病毒活性强于利巴韦林,且化合物BIX02189安全性良好。我们认为化合物BIX02189抗流感病毒新用途价值较高,具有应用前景。
附图说明
图1.化合物BIX02189阻断甲型A/Puerto Rico/8/1934(H1N1)感染A549细胞的活性评价结果。
图2.化合物BIX02189阻断甲型A/江西东湖/312/2006(H3N2)感染A549细胞的活性评价结果。
图3.化合物BIX02189阻断乙型B/江西新建/BV/39/2008感染MDCK细胞的活性评价结果。
图4.化合物BIX02189对A549细胞活力的影响
图5.化合物BIX02189对MDCK细胞活力的影响
具体实施方式
实施例1.检测流感病毒感染模型的原理
甲型A/Puerto Rico/8/1934(H1N1),甲型A/江西东湖/312/2006(H3N2)和乙型B/江西新建/BV/39/2008为经典的季节性流感毒株。肺组织是流感病毒感染的主要器官。本检测模型主要检测化合物对甲型流感病毒(A/Puerto Rico/8/1934和A/江西东湖/312/2006)感染肺癌A549细胞的抑制效果,以及化合物对乙型B/江西新建/BV/39/2008感染MDCK细胞的抑制效果。
本检测模型在感染前将化合物与细胞预孵育20h,随后将细胞感染病毒,并在感染后48h检测A549细胞活力,通过与溶剂对照组细胞和未感染病毒的正常细胞的细胞活力进行对比,计算化合物对病毒感染的抑制率。
实施例2.细胞活力检测模型的原理
ATP在细胞的各项生理过程中起着重要作用,为机体直接提供能量,是反映细胞活力的重要指标与活细胞数目成正相关。因此,通过定量检测细胞裂解液中ATP反映待测样本中活细胞数目。
本模型采用CellTiter-Luminescent Cell Viability Assay发光法细胞活力检测试剂盒(Promega公司)通过检测ATP定量A549细胞和MDCK细胞活力,评价化合物对A549细胞和MDCK细胞活力的影响。
实施例3.甲型A/Puerto Rico/8/1934(H1N1)感染A549细胞模型的实验方法和结果
将A549细胞以每孔4×104个细胞接种于96孔板,4小时后加入化合物BIX02189,终浓度分别为30μM、10μM、3μM和1μM,正常细胞对照组不加入任何化合物,溶剂对照组加入等体积DMSO,继续培养20小时。吸弃培养板中的培养基,用PBS润洗细胞一次,加入甲型A/Puerto Rico/8/1934病毒感染(M OI=0.01),37℃孵育1小时。吸弃培养基,PBS润洗一次,加入含受试化合物的培养基,正常细胞对照组加入培养基,溶剂对照组加入含等量DMSO的培养基。48小时后使用CellTiter-发光法细胞活力检测试剂盒(Promega公司)检测细胞活力,即测定细胞裂解液中的相对荧光素酶活性(relative luminescence units,RLUs)。按公式(1)和(2)计算各个实验组的细胞病变率和病毒抑制率。采用GraphPad Prism软件分析实验数据,以浓度-抑制率作散点图并用非线性拟合得到量效曲线,计算待测化合物的半数有效浓度EC50。
(1)细胞病变率%=(100-RLUs给药组(或RLUs溶剂对照组)/RLUs正常细胞对照组)×100%
(2)病毒抑制率%=(溶剂对照组细胞病变率-给药组细胞病变率)/溶剂对照组细胞病变率×100%
结果显示,化合物BIX02189可阻断甲型A/Puerto Rico/8/1934(H1N1)感染A549细胞,抗病毒活性优于一线抗病毒药物利巴韦林(结果见表1、量效曲线见附图1)。
表1化合物对甲型流感病毒A/Puerto Rico/8/1934(H1N1)感染A549细胞的活性评价结果
实施例4.甲型A/江西东湖/312/2006(H3N2)感染A549细胞模型的实验方法和结果
将A549细胞以每孔4×104个细胞接种于96孔板,4小时后加入化合物BIX02189,终浓度分别为30μM、10μM、3μM和1μM,正常细胞对照组不加入任何化合物,溶剂对照组加入等体积DMSO,继续培养20小时。吸弃培养板中的培养基,用PBS润洗细胞一次,加入甲型A/江西东湖/312/2006病毒感染(M OI=0.02),37℃孵育1小时。吸弃培养基,PBS润洗一次,加入含受试化合物的培养基,正常细胞对照组加入培养基,溶剂对照组加入含等量DMSO的培养基。48小时后使用CellTiter-发光法细胞活力检测试剂盒(Promega公司)检测细胞活力,即测定细胞裂解液中的相对荧光素酶活性(relative luminescence units,RLUs)。按公式(1)和(2)计算各个实验组的细胞病变率和病毒抑制率。采用GraphPad Prism软件分析实验数据,以浓度-抑制率作散点图并用非线性拟合得到量效曲线,计算待测化合物的半数有效浓度EC50。
(1)细胞病变率%=(100-RLUs给药组(或RLUs溶剂对照组)/RLUs正常细胞对照组)×100%
(2)病毒抑制率%=(溶剂对照组细胞病变率-给药组细胞病变率)/溶剂对照组细胞病变率×100%
结果显示,化合物BIX02189可阻断甲型A/江西东湖/312/2006(H3N2)感染A549细胞,抗病毒活性优于一线抗病毒药物利巴韦林(结果见表2、量效曲线见附图2)。
表2化合物对甲型流感病毒A/江西东湖/312/2006(H3N2)感染A549细胞的活性评价结果
实施例5.乙型B/江西新建/BV/39/2008感染MDCK细胞模型的实验方法和结果
将MDCK细胞以每孔4×104个细胞接种于96孔板,4小时后加入化合物BI X02189,终浓度分别为30μM、10μM、3μM和1μM,正常细胞对照组不加入任何化合物,溶剂对照组加入等体积DMSO,继续培养20小时。吸弃培养板中的培养基,用PBS润洗细胞一次,加入乙型B/江西新建/BV/39/2008病毒感染(100*TCID50),37℃孵育1小时。吸弃培养基,PBS润洗一次,加入含受试化合物的培养基,正常细胞对照组加入培养基,溶剂对照组加入含等量DMSO的培养基。48小时后使用CellTiter-发光法细胞活力检测试剂盒(Promega公司)检测细胞活力,即测定细胞裂解液中的相对荧光素酶活性(relative luminesc ence units,RLUs)。按公式(1)和(2)计算各个实验组的细胞病变率和病毒抑制率。采用GraphPad Prism软件分析实验数据,以浓度-抑制率作散点图并用非线性拟合得到量效曲线,计算待测化合物的半数有效浓度EC50。
(1)细胞病变率%=(100-RLUs给药组(或RLUs溶剂对照组)/RLUs正常细胞对照组)×100%
(2)病毒抑制率%=(溶剂对照组细胞病变率-给药组细胞病变率)/溶剂对照组细胞病变率×100%
结果显示,化合物BIX02189可阻断乙型B/江西新建/BV/39/2008感染MDC K细胞,抑制活性与一线抗病毒药物利巴韦林相当(结果见表3、量效曲线见附图3)。
表3化合物对乙型流感病毒B/江西新建/BV/39/2008感染MDCK活性评价结果
实施例6.检测化合物对细胞活力的影响
将A549细胞或MDCK细胞按8000个/孔密度接种至96孔板,每孔100μL细胞液,37℃,5%CO2培养24h。次日将不同浓度的受试化合物加至细胞,以等量DMSO(0.1%v/v)作为溶剂对照。继续培养48h后,每孔加入CellTiter-Glo试剂100μL,振荡混匀2min,室温孵育10min,测定各孔中的RLUs[Tang K,He S,Zhang X,et al.Tangeretin,an extract from Citruspeels,blocks cellular entry of arenaviruses that cause viral hemorrhagicfever.Antiviral Res.2018,160:87-93.]。以DMSO溶剂孔RLUs值为100%,计算加药孔的细胞存活率。
细胞存活率%=荧光强度给药组/荧光强度溶剂对照组×100%。
实验结果表明化合物BIX02189在其半数有效浓度下对A549细胞和MDCK细胞活力没有影响(结果见表4和表5、量效曲线见附图4和附图5)。
表4化合物BIX02189对A549细胞活力的影响
表5化合物BIX02189对MDCK细胞活力的影响
Claims (6)
2.根据权利要求1的应用,其特征在于,所述的药学上可接受的盐,包括药学上可接受的有机盐或无机盐,其中,所述的有机盐包括磺酸盐、羧酸盐、氨基酸盐以及脂肪酸盐,无机盐包括盐酸盐、溴酸盐、碘酸盐、硫酸盐、硫酸氢盐、磷酸盐、磷酸氢盐、磷酸二氢盐和硝酸盐。
3.根据权利要求2的应用,其特征在于,所述的磺酸盐包括含1-15个碳原子的烷基磺酸盐、苯磺酸盐、对甲苯磺酸盐、邻甲苯磺酸盐、间甲苯磺酸盐;羧酸盐包括酒石酸盐、马来酸盐、富马酸盐、枸橼酸盐、苹果酸盐、肉桂酸盐、苯甲酸盐、丙二酸盐、丁二酸盐、戊二酸盐、己二酸盐、双羟萘酸盐及乳酸盐;氨基酸盐包括谷氨酸盐、天冬氨酸盐;脂肪酸盐包括含2-18个碳原子的长链脂肪酸盐。
5.根据权利要求4的应用,其特征在于,所述的药物组合物还含有其它的抗病毒药。
6.根据权利要求1-4任一项的应用,其特征在于,所述的流感病毒包括甲型流感病毒、乙型流感病毒、丙型流感病毒或丁型流感病毒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011161113.1A CN114469938A (zh) | 2020-10-27 | 2020-10-27 | 化合物bix02189在制备抗流感病毒药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011161113.1A CN114469938A (zh) | 2020-10-27 | 2020-10-27 | 化合物bix02189在制备抗流感病毒药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114469938A true CN114469938A (zh) | 2022-05-13 |
Family
ID=81471213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011161113.1A Pending CN114469938A (zh) | 2020-10-27 | 2020-10-27 | 化合物bix02189在制备抗流感病毒药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114469938A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105431157A (zh) * | 2013-06-14 | 2016-03-23 | 普赛奥克苏斯治疗公司 | 用于b型腺病毒的给药方案及制剂 |
-
2020
- 2020-10-27 CN CN202011161113.1A patent/CN114469938A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105431157A (zh) * | 2013-06-14 | 2016-03-23 | 普赛奥克苏斯治疗公司 | 用于b型腺病毒的给药方案及制剂 |
Non-Patent Citations (5)
Title |
---|
REVATI J. TATAKE等: "Identification of pharmacological inhibitors of the MEK5/ERK5 pathway", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 377, pages 120 - 125, XP025587434, DOI: 10.1016/j.bbrc.2008.09.087 * |
SACHIKO KAMAKURA等: "Activation of the Protein Kinase ERK5/BMK1 by Receptor Tyrosine Kinases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 37, pages 26563 - 26571 * |
STEPHAN LUDWIGA等: "MEK inhibition impairs in£uenza B virus propagation without emergence of resistant variants", FEBS LETTERS, vol. 561, pages 37 - 43 * |
STEPHAN PLESCHKA等: "Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade", NATURE CELL BIOLOGY, vol. 3, pages 301 - 306 * |
王玉涛等: "流感病毒诱导的宿主细胞信号通路 —潜在抗病毒药物靶点", 中国病毒病杂志, vol. 3, no. 4, pages 250 - 254 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102607599B1 (ko) | 인플루엔자의 치료 방법 | |
EA037529B1 (ru) | Способ получения соединения для ингибирования репликации вирусов гриппа | |
CN103648491B (zh) | 用于抑制流感病毒复制的方法和药物组合物 | |
WO2019100689A1 (zh) | 大环内酯类抗生素在阻断流感病毒感染中的应用 | |
WO2022142727A1 (zh) | 一种抗病毒化合物及其制备方法 | |
US20230190713A1 (en) | Anti-rna virus drug and application thereof | |
US10221152B2 (en) | Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus | |
US11433080B2 (en) | Antiviral treatment | |
US7341988B2 (en) | Method of treating influenza with geranyl-geranyl acetone | |
CN114469938A (zh) | 化合物bix02189在制备抗流感病毒药物中的应用 | |
CN114377015B (zh) | 萘哌地尔在制备抗流感病毒药物中的应用 | |
CN114377009A (zh) | Sb216763在制备抗流感病毒药物中的应用 | |
WO2017092698A1 (zh) | 一种能够抑制流感病毒聚合酶亚基pa与pb1相互作用的化合物 | |
CN114377018B (zh) | 硝呋莫司在制备抗流感病毒药物中的应用 | |
US10792275B2 (en) | Inhibiting binding of influenza-virus PB2 subunit to RNA cap | |
CN111568900A (zh) | 吲哚美辛在抗冠状病毒感染中的应用 | |
CN110013482A (zh) | 帕纳替尼在制备治疗流感病毒感染的药物中的应用 | |
CN110151767B (zh) | Gnf-7在制备治疗流感病毒感染的药物中的应用 | |
CN116672329A (zh) | 橙黄决明素在制备抗流感病毒药物中的应用 | |
CN116672337A (zh) | 甘松新酮在制备抗流感病毒药物中的应用 | |
US20220204501A1 (en) | Enterovirus inhibitor | |
CN110314162A (zh) | 达沙替尼在制备治疗流感病毒感染的药物中的应用 | |
CN110151765A (zh) | Azd1480在制备治疗流感病毒感染的药物中的应用 | |
TWI530284B (zh) | 馬替麥考酚酯或其鹽類用於製備抗流感病毒之藥物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220513 |